Inhibition of casein kinase 2 prevents growth of human osteosarcoma

Takahashi,Kengo; Setoguchi,Takao; Tsuru,Arisa; Saitoh,Yoshinobu; Nagano,Satoshi; Ishidou,Yasuhiro; Maeda,Shingo; Furukawa,Tatsuhiko; Komiya,Setsuro

doi:10.3892/or.2016.5310

Inhibition of casein kinase 2 prevents growth of human osteosarcoma

Authors:
- Kengo Takahashi
- Takao Setoguchi
- Arisa Tsuru
- Yoshinobu Saitoh
- Satoshi Nagano
- Yasuhiro Ishidou
- Shingo Maeda
- Tatsuhiko Furukawa
- Setsuro Komiya
View Affiliations

Affiliations: Department of Orthopaedic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan, The Near-Future Locomotor Organ Medicine Creation Course (Kusunoki Kai), Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan, Department of Medical Joint Materials, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan, Center for the Research of Advanced Diagnosis and Therapy of Cancer, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan
Published online on: December 9, 2016 https://doi.org/10.3892/or.2016.5310
Pages: 1141-1147

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

High-dose chemotherapy and surgical treatment have improved the prognosis of osteosarcoma. However, more than 20% of patients with osteosarcoma still have a poor prognosis. We investigated the expression and function of casein kinase 2 (CK2) in osteosarcoma growth. We then examined the effects of CX-4945, a CK2 inhibitor, on osteosarcoma growth in vitro and in vivo to apply our findings to the clinical setting. We examined the expression of CK2α and CK2β by western blot analysis, and performed WST-1 assays using CK2α and CK2β siRNA or CX-4945. Flow cytometry and western blot analyses were performed to evaluate apoptotic cell death. Xenograft models were used to examine the effect of CX-4945 in vivo. Western blot analysis revealed upregulation of CK2α and CK2β in human osteosarcoma cell lines compared with human osteoblast cells or mesenchymal stem cells. WST assay showed that knockdown of CK2α or CK2β by siRNA inhibited the proliferation of human osteosarcoma cells. Treatment with 3 µM of CX-4945 inhibited osteosarcoma cell proliferation; however, the same concentration of CX-4945 did not affect the proliferation of human mesenchymal stem cells. Additionally, treatment with CX-4945 inhibited the proliferation of human osteosarcoma cells in a dose-dependent manner. Western blot and flow cytometry analyses showed that treatment with CX-4945 promoted apoptotic death of osteosarcoma cells. The xenograft model showed that treatment with CX-4945 significantly prevented osteosarcoma growth in vivo compared with control vehicle treatment. Our findings indicate that CK2 may be an attractive therapeutic target for treating osteosarcoma.

View Figures

View References

1	Isakoff MS, Bielack SS, Meltzer P and Gorlick R: Osteosarcoma: Current treatment and a collaborative pathway to success. J Clin Oncol. 33:3029–3035. 2015. View Article : Google Scholar : PubMed/NCBI
2	Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, et al: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 20:776–790. 2002. View Article : Google Scholar : PubMed/NCBI
3	He JP, Hao Y, Wang XL, Yang XJ, Shao JF, Guo FJ and Feng JX: Review of the molecular pathogenesis of osteosarcoma. Asian Pac J Cancer Prev. 15:5967–5976. 2014. View Article : Google Scholar : PubMed/NCBI
4	Hanif IM, Hanif IM, Shazib MA, Ahmad KA and Pervaiz S: Casein Kinase II: An attractive target for anti-cancer drug design. Int J Biochem Cell Biol. 42:1602–1605. 2010. View Article : Google Scholar : PubMed/NCBI
5	Meggio F and Pinna LA: One-thousand-and-one substrates of protein kinase CK2? FASEB J. 17:349–368. 2003. View Article : Google Scholar : PubMed/NCBI
6	Ahmad KA, Harris NH, Johnson AD, Lindvall HC, Wang G and Ahmed K: Protein kinase CK2 modulates apoptosis induced by resveratrol and epigallocatechin-3-gallate in prostate cancer cells. Mol Cancer Ther. 6:1006–1012. 2007. View Article : Google Scholar : PubMed/NCBI
7	Faust RA, Gapany M, Tristani P, Davis A, Adams GL and Ahmed K: Elevated protein kinase CK2 activity in chromatin of head and neck tumors: Association with malignant transformation. Cancer Lett. 101:31–35. 1996. View Article : Google Scholar : PubMed/NCBI
8	Kim JS, Eom JI, Cheong JW, Choi AJ, Lee JK, Yang WI and Min YH: Protein kinase CK2alpha as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia. Clin Cancer Res. 13:1019–1028. 2007. View Article : Google Scholar : PubMed/NCBI
9	Liu Y, Amin EB, Mayo MW, Chudgar NP, Bucciarelli PR, Kadota K, Adusumilli PS and Jones DR: CK2α drives lung cancer metastasis by targeting BRMS1 nuclear export and degradation. Cancer Res. 76:2675–2686. 2016. View Article : Google Scholar : PubMed/NCBI
10	Siddiqui-Jain A, Drygin D, Streiner N, Chua P, Pierre F, O'Brien SE, Bliesath J, Omori M, Huser N, Ho C, et al: CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 70:10288–10298. 2010. View Article : Google Scholar : PubMed/NCBI
11	Ferguson AD, Sheth PR, Basso AD, Paliwal S, Gray K, Fischmann TO and Le HV: Structural basis of CX-4945 binding to human protein kinase CK2. FEBS Lett. 585:104–110. 2011. View Article : Google Scholar : PubMed/NCBI
12	Cozza G, Pinna LA and Moro S: Protein kinase CK2 inhibitors: A patent review. Expert Opin Ther Pat. 22:1081–1097. 2012. View Article : Google Scholar : PubMed/NCBI
13	Kim J and Kim SH: Druggability of the CK2 inhibitor CX-4945 as an anticancer drug and beyond. Arch Pharm Res. 35:1293–1296. 2012. View Article : Google Scholar : PubMed/NCBI
14	Sarno S, Papinutto E, Franchin C, Bain J, Elliott M, Meggio F, Kazimierczuk Z, Orzeszko A, Zanotti G, Battistutta R, et al: ATP site-directed inhibitors of protein kinase CK2: An update. Curr Top Med Chem. 11:1340–1351. 2011. View Article : Google Scholar : PubMed/NCBI
15	Bettendorff L, Wirtzfeld B, Makarchikov AF, Mazzucchelli G, Frédérich M, Gigliobianco T, Gangolf M, De Pauw E, Angenot L and Wins P: Discovery of a natural thiamine adenine nucleotide. Nat Chem Biol. 3:211–212. 2007. View Article : Google Scholar : PubMed/NCBI
16	Pizzi M, Piazza F, Agostinelli C, Fuligni F, Benvenuti P, Mandato E, Casellato A, Rugge M, Semenzato G and Pileri SA: Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth. Oncotarget. 6:6544–6552. 2015. View Article : Google Scholar : PubMed/NCBI
17	Nakamura S, Nagano S, Nagao H, Ishidou Y, Yokouchi M, Abematsu M, Yamamoto T, Komiya S and Setoguchi T: Arsenic trioxide prevents osteosarcoma growth by inhibition of GLI transcription via DNA damage accumulation. PLoS One. 8:e694662013. View Article : Google Scholar : PubMed/NCBI
18	Nagao H, Ijiri K, Hirotsu M, Ishidou Y, Yamamoto T, Nagano S, Takizawa T, Nakashima K, Komiya S and Setoguchi T: Role of GLI2 in the growth of human osteosarcoma. J Pathol. 224:169–179. 2011. View Article : Google Scholar : PubMed/NCBI
19	Kulbe H, Iorio F, Chakravarty P, Milagre CS, Moore R, Thompson RG, Everitt G, Canosa M, Montoya A, Drygin D, et al: Integrated transcriptomic and proteomic analysis identifies protein kinase CK2 as a key signaling node in an inflammatory cytokine network in ovarian cancer cells. Oncotarget. 7:15648–15661. 2016.PubMed/NCBI
20	Son YH, Song JS, Kim SH and Kim J: Pharmacokinetic characterization of CK2 inhibitor CX-4945. Arch Pharm Res. 36:840–845. 2013. View Article : Google Scholar : PubMed/NCBI
21	Son YH, Moon SH and Kim J: The protein kinase 2 inhibitor CX-4945 regulates osteoclast and osteoblast differentiation in vitro. Mol Cells. 36:417–423. 2013. View Article : Google Scholar : PubMed/NCBI
22	Trembley JH, Unger GM, Korman VL, Abedin MJ, Nacusi LP, Vogel RI, Slaton JW, Kren BT and Ahmed K: Tenfibgen ligand nanoencapsulation delivers bi-functional anti-CK2 RNAi oligomer to key sites for prostate cancer targeting using human xenograft tumors in mice. PLoS One. 9:e1099702014. View Article : Google Scholar : PubMed/NCBI
23	Unger GM, Kren BT, Korman VL, Kimbrough TG, Vogel RI, Ondrey FG, Trembley JH and Ahmed K: Mechanism and efficacy of sub-50-nm tenfibgen nanocapsules for cancer cell-directed delivery of anti-CK2 RNAi to primary and metastatic squamous cell carcinoma. Mol Cancer Ther. 13:2018–2029. 2014. View Article : Google Scholar : PubMed/NCBI
24	Giusiano S, Cochet C, Filhol O, Duchemin-Pelletier E, Secq V, Bonnier P, Carcopino X, Boubli L, Birnbaum D, Garcia S, et al: Protein kinase CK2α subunit over-expression correlates with metastatic risk in breast carcinomas: Quantitative immunohistochemistry in tissue microarrays. Eur J Cancer. 47:792–801. 2011. View Article : Google Scholar : PubMed/NCBI
25	Gapany M, Faust RA, Tawfic S, Davis A, Adams GL and Ahmed K: Association of elevated protein kinase CK2 activity with aggressive behavior of squamous cell carcinoma of the head and neck. Mol Med. 1:659–666. 1995.PubMed/NCBI
26	Yang W, Liu X, Choy E, Mankin H, Hornicek FJ and Duan Z: Targeting hedgehog-GLI-2 pathway in osteosarcoma. J Orthop Res. 31:502–509. 2013. View Article : Google Scholar : PubMed/NCBI
27	Saitoh Y, Setoguchi T, Nagata M, Tsuru A, Nakamura S, Nagano S, Ishidou Y, Nagao-Kitamoto H, Yokouchi M, Maeda S, et al: Combination of Hedgehog inhibitors and standard anticancer agents synergistically prevent osteosarcoma growth. Int J Oncol. 48:235–242. 2016.PubMed/NCBI
28	Nagao-Kitamoto H, Setoguchi T, Kitamoto S, Nakamura S, Tsuru A, Nagata M, Nagano S, Ishidou Y, Yokouchi M, Kitajima S, et al: Ribosomal protein S3 regulates GLI2-mediated osteosarcoma invasion. Cancer Lett 356B. 855–861. 2015. View Article : Google Scholar
29	Nagao-Kitamoto H, Nagata M, Nagano S, Kitamoto S, Ishidou Y, Yamamoto T, Nakamura S, Tsuru A, Abematsu M, Fujimoto Y, et al: GLI2 is a novel therapeutic target for metastasis of osteosarcoma. Int J Cancer. 136:1276–1284. 2015. View Article : Google Scholar : PubMed/NCBI
30	Hirotsu M, Setoguchi T, Sasaki H, Matsunoshita Y, Gao H, Nagao H, Kunigou O and Komiya S: Smoothened as a new therapeutic target for human osteosarcoma. Mol Cancer. 9:52010. View Article : Google Scholar : PubMed/NCBI
31	Zhang S, Yang YL, Wang Y, You B, Dai Y, Chan G, Hsieh D, Kim IJ, Fang LT, Au A, et al: CK2α, over-expressed in human malignant pleural mesothelioma, regulates the Hedgehog signaling pathway in mesothelioma cells. J Exp Clin Cancer Res. 33:932014. View Article : Google Scholar : PubMed/NCBI
32	Tang AQ, Cao XC, Tian L, He L and Liu F: Apigenin inhibits the self-renewal capacity of human ovarian cancer SKOV3-derived sphere-forming cells. Mol Med Rep. 11:2221–2226. 2015.PubMed/NCBI
33	Wu D, Sui C, Meng F, Tian X, Fu L, Li Y, Qi X, Cui H, Liu Y and Jiang Y: Stable knockdown of protein kinase CK2-alpha (CK2α) inhibits migration and invasion and induces inactivation of hedgehog signaling pathway in hepatocellular carcinoma Hep G2 cells. Acta Histochem. 116:1501–1508. 2014. View Article : Google Scholar : PubMed/NCBI
34	Zhang S, Wang Y, Mao JH, Hsieh D, Kim IJ, Hu LM, Xu Z, Long H, Jablons DM and You L: Inhibition of CK2α down-regulates Hedgehog/Gli signaling leading to a reduction of a stem-like side population in human lung cancer cells. PLoS One. 7:e389962012. View Article : Google Scholar : PubMed/NCBI
35	Jin Z, Mei W, Strack S, Jia J and Yang J: The antagonistic action of B56-containing protein phosphatase 2As and casein kinase 2 controls the phosphorylation and Gli turnover function of Daz interacting protein 1. J Biol Chem. 286:36171–36179. 2011. View Article : Google Scholar : PubMed/NCBI
36	Jia H, Liu Y, Xia R, Tong C, Yue T, Jiang J and Jia J: Casein kinase 2 promotes Hedgehog signaling by regulating both smoothened and Cubitus interruptus. J Biol Chem. 285:37218–37226. 2010. View Article : Google Scholar : PubMed/NCBI
37	Kim J, Choi WJ, Moon SH, Jung J, Park JK, Kim SH and Lee JO: Micropillar arrays as potential drug screens: Inhibition of micropillar-mediated activation of the FAK-Src-paxillin signaling pathway by the CK2 inhibitor CX-4945. Acta Biomater. 27:13–20. 2015. View Article : Google Scholar : PubMed/NCBI
38	Bian Y, Han J, Kannabiran V, Mohan S, Cheng H, Friedman J, Zhang L, VanWaes C and Chen Z: MEK inhibitor PD-0325901 overcomes resistance to CK2 inhibitor CX-4945 and exhibits anti-tumor activity in head and neck cancer. Int J Biol Sci. 11:411–422. 2015. View Article : Google Scholar : PubMed/NCBI
39	Intemann J, Saidu NE, Schwind L and Montenarh M: ER stress signaling in ARPE-19 cells after inhibition of protein kinase CK2 by CX-4945. Cell Signal. 26:1567–1575. 2014. View Article : Google Scholar : PubMed/NCBI
40	Zhang S, Long H, Yang YL, Wang Y, Hsieh D, Li W, Au A, Stoppler HJ, Xu Z, Jablons DM, et al: Inhibition of CK2α down-regulates Notch1 signalling in lung cancer cells. J Cell Mol Med. 17:854–862. 2013. View Article : Google Scholar : PubMed/NCBI
41	Bliesath J, Huser N, Omori M, Bunag D, Proffitt C, Streiner N, Ho C, Siddiqui-Jain A, O'Brien SE, Lim JK, et al: Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells. Cancer Lett. 322:113–118. 2012. View Article : Google Scholar : PubMed/NCBI
42	Martins LR, Lúcio P, Melão A, Antunes I, Cardoso BA, Stansfield R, Bertilaccio MT, Ghia P, Drygin D, Silva MG, et al: Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia. Leukemia. 28:179–182. 2014. View Article : Google Scholar : PubMed/NCBI